Context Therapeutics (NASDAQ:CNTX - Get Free Report)'s stock had its "sell (d-)" rating reiterated by investment analysts at Weiss Ratings in a report released on Friday,Weiss Ratings reports.
Other analysts also recently issued reports about the stock. Piper Sandler reiterated an "overweight" rating and issued a $4.00 price objective (down from $4.50) on shares of Context Therapeutics in a report on Thursday, June 26th. Guggenheim started coverage on shares of Context Therapeutics in a research note on Thursday, September 18th. They issued a "buy" rating and a $5.00 price target on the stock. D. Boral Capital reiterated a "buy" rating and issued a $9.00 price target on shares of Context Therapeutics in a research note on Thursday, October 16th. HC Wainwright lowered their target price on Context Therapeutics from $5.00 to $4.00 and set a "buy" rating on the stock in a research report on Thursday, August 7th. Finally, Cantor Fitzgerald began coverage on Context Therapeutics in a research report on Thursday, October 2nd. They issued an "overweight" rating on the stock. One analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Context Therapeutics has an average rating of "Moderate Buy" and a consensus target price of $5.20.
Get Our Latest Stock Report on CNTX
Context Therapeutics Stock Down 1.6%
Context Therapeutics stock traded down $0.02 during mid-day trading on Friday, hitting $1.26. 110,085 shares of the company's stock were exchanged, compared to its average volume of 499,786. The firm has a market capitalization of $113.02 million, a P/E ratio of -3.50 and a beta of 1.93. The company's 50 day simple moving average is $1.02 and its 200-day simple moving average is $0.83. Context Therapeutics has a fifty-two week low of $0.49 and a fifty-two week high of $2.40.
Context Therapeutics (NASDAQ:CNTX - Get Free Report) last released its quarterly earnings results on Wednesday, August 6th. The company reported ($0.09) EPS for the quarter, missing analysts' consensus estimates of ($0.06) by ($0.03). Research analysts expect that Context Therapeutics will post -0.51 EPS for the current year.
Hedge Funds Weigh In On Context Therapeutics
A hedge fund recently raised its stake in Context Therapeutics stock. Clear Harbor Asset Management LLC increased its holdings in shares of Context Therapeutics Inc. (NASDAQ:CNTX - Free Report) by 60.5% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 92,804 shares of the company's stock after acquiring an additional 35,000 shares during the quarter. Clear Harbor Asset Management LLC owned about 0.10% of Context Therapeutics worth $90,000 as of its most recent SEC filing. 14.03% of the stock is owned by hedge funds and other institutional investors.
About Context Therapeutics
(
Get Free Report)
Context Therapeutics Inc, a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Context Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Context Therapeutics wasn't on the list.
While Context Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
